PharmHunterJen said:DerekSJ_a1c said: ...I stopped maintenance dosing and regained all the weight...
Can confirm. Same sequence, different timescale. Nothing to add that would improve it.
josh_phd_bmore said:DerekSJ_a1c said: ...the STEP extension data on maintenance dosing is concerning...
Thank you for spelling out the reasoning rather than just the conclusion. Adding it to my notes with a link back to this thread.
Clinical perspective, offered as context rather than as advice.
STEP 5 long-term data on maintenance dosing: the 104-week (2-year) extension showed sustained weight loss of -15.2% with continued semaglutide vs weight regain in the discontinuation group[1].
Key insight: weight loss continued to accrue between weeks 68 and 104 in many patients, suggesting the nadir may not occur until year 2+. The 68-week primary endpoint in most trials may underestimate maximal efficacy.
This supports long-term, open-ended treatment rather than fixed-duration "courses" of therapy.
[1] Garvey WT, et al. Nat Med. 2022;28:2083-2091.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL Biochemandrew_nyc said:STEP 5 long-term data on maintenance dosing: the 104-week (2-year) extension showed sustained weight loss of -15.2% with continued semaglutide vs…
This is my experience too, for whatever a second data point is worth. The detail I would add is minor and it is already implied above.